Eli Lilly and Co - 80% of Omvoh patients maintain long-term remission

Eli Lilly and Co - 80% of Omvoh patients maintain long-term remission

Eli Lilly and Co has announced significant long-term results from its Phase 3 LUCENT-3 study, demonstrating the sustained efficacy of Omvoh (mirikizumab-mrkz) in treating moderately to severely active ulcerative colitis (UC). The study, presented at the United European Gastroenterology (UEG) Week in Berlin, showed that approximately 80% of patients who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission over four years .

The study, which included patients who had previously failed a biologic or advanced therapy, reported the following outcomes after four years of treatment among those who achieved clinical remission at one year:
- 78% achieved corticosteroid-free clinical remission
- 78% sustained long-term clinical remission
- 81% sustained endoscopic remission
- 90% achieved remission on the Inflammatory Bowel Disease Questionnaire (IBDQ)
- 66% achieved histological-endoscopic mucosal improvement
- 93% achieved a 3 or more-point reduction on the Urgency Numeric Rating Scale (UNRS)
- 74% achieved UNRS = 0 or 1

These results highlight Omvoh's potential as a highly effective biologic for UC management, offering sustained clinical, endoscopic, and steroid-free remission over four years, as well as improvement in bowel urgency, a significant burden for patients .

Mark Genovese, M.D., senior vice president of Lilly Immunology development, noted, "With these results, Omvoh continues to set a high standard as the first and only IL-23p19 with evidence of sustained efficacy and consistent safety in ulcerative colitis over four years" .

Lilly is advancing combination studies of mirikizumab with other therapies to deliver breakthrough induction efficacy while maintaining long-term remission and safety, including studies with eltrekibart and LY4268989 . Omvoh has received regulatory approvals for the treatment of moderately to severely active UC and moderately to severely active Crohn's disease in adults and has been approved in 44 countries around the world .